Cargando…

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are currently conducted only in research settings. Yet, US Food and Drug Administration approval of a disease‐modifying treatment for symptomatic individuals, improved understanding of the “preclinical” phase of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erickson, Claire M., Clark, Lindsay R., Ketchum, Fred B., Chin, Nathaniel A., Gleason, Carey E., Largent, Emily A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405485/ https://www.ncbi.nlm.nih.gov/pubmed/36035626 http://dx.doi.org/10.1002/dad2.12339

Ejemplares similares

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022)

Research Participant Interest in Alzheimer’s Disease Biomarker Disclosure
por: Erickson, Claire, et al.
Publicado: (2020)

Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
por: Erickson, Claire M., et al.
Publicado: (2021)

What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer’s Disease Biomarker Research? A Qualitative Vignette Analysis
por: Ketchum, Fred B., et al.
Publicado: (2022)

Predictors of positive or negative reactions to learning Alzheimer’s biomarker results
por: Erickson, Claire, et al.
Publicado: (2021)

Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences
por: Erickson, Claire M., et al.
Publicado: (2021)

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
por: Ketchum, Fred B., et al.
Publicado: (2023)

Anticipated reactions to learning Alzheimer’s disease biomarker results
por: Clark, Lindsay R., et al.
Publicado: (2022)

Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results
por: Erickson, Claire M., et al.
Publicado: (2022)

Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort
por: Erickson, Claire M., et al.
Publicado: (2023)

Key Elements of Effective and Practical Disclosure Policies for Health Science Journals
por: Sass, Jennifer
Publicado: (2009)

Cardiology clinic patient attitudes toward and potential personal utility of genetic testing: Findings from a unique multiracial clinical sample
por: Erickson, Claire M., et al.
Publicado: (2022)

US state policies for Medicaid coverage of donor human milk
por: Rose, Allison T., et al.
Publicado: (2022)

Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018)

Disclosure of medical errors to patients in China
por: Gao, Lei, et al.
Publicado: (2015)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Realigning science, society and policy in uncertain times
por: Mehta, Goverdhan, et al.
Publicado: (2020)

Biological sex differences in Alzheimer's preclinical research: A call to action
por: Waters, Ansley, et al.
Publicado: (2021)

Full Disclosure Policy
por: Goehl, TJ
Publicado: (2003)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
por: Kuehn, Carrie M.
Publicado: (2019)

Of risks and regulations: how leading U.S. nanoscientists form policy stances about nanotechnology
por: Corley, Elizabeth A., et al.
Publicado: (2009)

Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findings
por: McGuire, Amy L., et al.
Publicado: (2014)

How would preclinical Alzheimer’s disease (AD pathology) occur? An insight from a genomic instability mouse model
por: Rao, Chinthalapally V., et al.
Publicado: (2021)

Thresholds and Endocrine Disruptors: An Endocrine Society Policy Perspective
por: Demeneix, Barbara, et al.
Publicado: (2020)

Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results
por: Largent, Emily A., et al.
Publicado: (2020)

What is paradoxical lucidity? The answer begins with its definition
por: Peterson, Andrew, et al.
Publicado: (2021)

Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease
por: Cardozo, Timothy, et al.
Publicado: (2020)

Reimagining the research-practice relationship: policy recommendations for informatics-enabled evidence-generation across the US health system
por: Embi, Peter J, et al.
Publicado: (2019)

HIV disclosure as practice and public policy
por: Adam, Barry D., et al.
Publicado: (2015)

The Economics of Reproducibility in Preclinical Research
por: Freedman, Leonard P., et al.
Publicado: (2015)

Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest
por: Meslin, Eric M., et al.
Publicado: (2015)

From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2018)

Increased intron retention is linked to Alzheimer’s disease
por: Ong, Chin-Tong, et al.
Publicado: (2019)

A Guide to Reproducibility in Preclinical Research
por: Samsa, Greg, et al.
Publicado: (2019)

Breaking down silos: engaging students to help fix the US health care system
por: Kumarasamy, Mathu A, et al.
Publicado: (2015)

Sexing Bones: Improving Transparency of Sex Reporting to Address Bias Within Preclinical Studies
por: Sharma, Aikta, et al.
Publicado: (2022)

Enrichment of novel Tau isoform with altered biochemical properties in Alzheimer’s disease
por: Ong, Chin-Tong
Publicado: (2023)

A revisit of rod microglia in preclinical studies
por: Rao, Yanxia, et al.
Publicado: (2017)

How Can We Bring Public Health in All Policies? Strategies for Healthy Societies
por: Bert, Fabrizio, et al.
Publicado: (2015)

Where is the policy in health policy and systems research agenda?
por: Ghaffar, Abdul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hk2lethve900gom02vrdk85a62